Abstract:beta-Lapachone (LPC) is a novel cytotoxic agent that is bioactivated by NADP(H): quinone oxidoreductase 1 (NQO1), an enzyme elevated in a variety of tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer, liver cancer, and breast cancer. Despite its unique mechanism of action, its clinical evaluation has been largely hindered by low water solubility, short blood half-life, and narrow therapeutic window. Although encapsulation into poly(ethylene glycol)-b-poly(d,l-lactic acid) (PEG-PLA) micelles could modestly improve its solubility and prolong its half-life, the extremely fast intrinsic crystallization tendency of LPC prevents drug loading higher than similar to 2 wt %. The physical stability of the LPC-loaded micelles is also far from satisfactory for further development. In this study, we demonstrate that paclitaxel (PTX), a front-line drug for many cancers, can provide two functions when coencapsulated together with LPC in the PEG-PLA micelles; first, as a strong crystallization inhibitor for LPC, thus to significantly increase the LPC encapsulation efficiency in the micelle from 11.7 +/- 2.4% to 100.7 +/- 2.2%. The total drug loading efficiency of both PTX and LPC in the combination polymeric micelle reached 100.3 +/- 3.0%, and the drug loading density reached 33.2 +/- 1.0%. Second, the combination of LPC/PTX demonstrates strong synergistic cytotoxicity effect against the NQO1 overexpressing cancer cells, including A549 NSCLC cells, and several pancreatic cancer cells (combination index <1). In vitro drug release study showed that LPC was released faster than PTX either in phosphate-buffered saline (PH = 7.4) or in 1 M sodium salicylate, which agrees with the desired dosing sequence of the two drugs to exert synergistic pharmacologic effect at different cell checkpoints. The PEG-PLA micelles coloaded with LPC and PTX offer a novel nanotherapeutic, with high drug loading, sufficient physical stability, and biological synergy to increase drug delivery efficiency and optimize the therapeutic window for NOQ1-targeted therapy of cancer.

Tailored Beta-Lapachone Nanomedicines for Cancer-Specific Therapy

Beta-lapachone Micellar Nanotherapeutics for Non-Small Cell Lung Cancer Therapy.

Triggering Multiple Modalities of Cell Death Via Dual-Responsive Nanomedicines to Address the Narrow Therapeutic Window of Β-Lapochone

Triggering multiple modalities of cell death via dual-responsive nanomedicines to address the narrow therapeutic window of β-lapachone

Lysosome-Oriented, Dual-Stage Ph-Responsive Polymeric Micelles For Beta-Lapachone Delivery

Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy

Novel Nanosystem to Enhance the Antitumor Activity of Lapatinib in Breast Cancer Treatment: Therapeutic Efficacy Evaluation.

Mechanistic Studies of Cancer Cell Mitochondria- and NQO1-mediated Redox Activation of Beta-Lapachone, a Potentially Novel Anticancer Agent

Lysosome-oriented, dual-stage pH-responsive polymeric micelles for β-Lapachone delivery

Enzyme-triggered Deep Tumor Penetration of a Dual-Drug Nanomedicine Enables an Enhanced Cancer Combination Therapy

Cancer Chemotherapy with Lipid-Based Nanocarriers

LAPONITE? nanodisk-based platforms for cancer diagnosis and therapy (Jul, 10.1039/d2ma00637e, 2022)

Β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy As Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy.

A novel multifunctional nanoparticles formed by molecular recognition between AS1411 aptamer and redox-responsive paclitaxel-nucleoside analogue prodrug for combination treatment of β-lapachone and paclitaxel.

Efficacy of beta-lapachone in pancreatic cancer treatment: Exploiting the novel, therapeutic target NQO1

Enhanced in Vivo Antitumor Efficacy of Doxorubicin Encapsulated Within Laponite Nanodisks.

A Dual Responsive Nitric Oxide / Β-Lapachone Co-Delivery Platform for Redox Imbalance-Enhanced Tumor Therapy

Lapatinib-loaded Acidity-Triggered Charge Switchable Polycarbonate-Doxorubicin Conjugate Micelles for Synergistic Breast Cancer Chemotherapy.

Lapatinib-incorporated Lipoprotein-Like Nanoparticles: Preparation and a Proposed Breast Cancer-Targeting Mechanism

Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy

A Β-Lapachone-loaded Iron-Polyphenol Nanocomplex Enhances Chemodynamic Therapy Through Cascade Amplification of ROS in Tumor